[Treatment of hyperplasia endometrium with GNRH agonists].

In: Ginekologia polska · 2003 · vol. 74(9) , pp. 836–9 · PMID:14674133 · W2474521548
article OA: closed CC0
View on OpenAlex View on PubMed
AI-generated summary by claude@2026-06, 2026-06-10

This study treated 15 women with simple endometrial hyperplasia using a GnRH agonist for 3 months, resulting in 100% efficacy with observed endometrial atrophy and decreased thickness.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVES: Untreated hormonal disturbances connected with unbalanced estrogen serum concentrations can influence on pathological proliferation of endometrium. The aim of the study is to assess the effect of GnRH agonists on endometrium in women consulted due to simple hyperplasia endometrium. MATERIAL AND METHODS: 15 women in the mean age 48.5 +/- 3.5 years with the histopathological diagnosis of simple hyperplasia were treated with trioptorelin during 3 months. After therapy all patients were undergone transvaginal ultrasonography and endometrial biopsy. RESULTS: Atrophic endometrium were observed in all women after a 3-month therapy. The thickness of endometrium decreased from 10.21 +/- 3.2 mm to 3.94 +/- 1.56 mm. CONCLUSIONS: The efficacy of the therapy of simple hyperplasia in women with GnRH agonist was 100%.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

SciLite annotations

chemicals 1
estrogen

Source provenance

openalex
last seen: 2026-05-10T10:22:13.955585+00:00
scilite
last seen: 2026-05-18T04:57:49.680383+00:00
License: CC0 · commercial use OK